Is It Too Late To Consider Celcuity (CELC) After An 8x One Year Surge

Simply Wall St.02-07

If you are looking at Celcuity and wondering whether the current share price still offers value, this article will walk through what the numbers are actually saying about the stock. After a very large...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609526849?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-07 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609526849","market":"sg","top_or_hot":-1,"title":"Is It Too Late To Consider Celcuity (CELC) After An 8x One Year Surge","media":"Simply Wall St.","content":"<div>\n<p>If you are looking at Celcuity and wondering whether the current share price still offers value, this article will walk through what the numbers are actually saying about the stock. After a very large...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/is-it-too-late-to-consider-celcuity-celc-after-an-8x-one-yea\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Celcuity (CELC) After An 8x One Year Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Celcuity (CELC) After An 8x One Year Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-07 23:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/is-it-too-late-to-consider-celcuity-celc-after-an-8x-one-yea><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are looking at Celcuity and wondering whether the current share price still offers value, this article will walk through what the numbers are actually saying about the stock. After a very large...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/is-it-too-late-to-consider-celcuity-celc-after-an-8x-one-yea\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/is-it-too-late-to-consider-celcuity-celc-after-an-8x-one-yea","article_id":"2609526849","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/is-it-too-late-to-consider-celcuity-celc-after-an-8x-one-yea","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609526849","pubTimestamp":1770477131,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are looking at Celcuity and wondering whether the current share price still offers value, this article will walk through what the numbers are actually saying about the stock.\nAfter a very large 1 year return of around 8x and a 6.2% gain year to date, the share price has recently seen a 2.4% 7 day decline and a 2.2% 30 day decline, which may have some investors reassessing the balance between potential and risk.\nRecent news around Celcuity has largely focused on its position as a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技"},"translate_title":"Celcuity(CELC)一年飙升8倍后，现在考虑是否为时已晚","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"CELC":1.5},"content_text":"If you are looking at Celcuity and wondering whether the current share price still offers value, this article will walk through what the numbers are actually saying about the stock. After a very large 1 year return of around 8x and a 6.2% gain year to date, the share price has recently seen a 2.4% 7 day decline and a 2.2% 30 day decline, which may have some investors reassessing the balance between potential and risk. Recent news around Celcuity has largely focused on its position as a clinical stage biotechnology company and ongoing progress in its pipeline. This has kept attention on how future milestones could affect the business. Coverage has also highlighted the stock's past long term price performance, adding more context to the sharp moves investors have seen on the chart. Celcuity currently holds a valuation score of 2 out of 6. Next we will look at how different traditional valuation approaches assess the stock and then finish with a framework that can help you interpret those results in a more complete way.  Celcuity scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Celcuity Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes forecasts of a company’s future cash flows and discounts them back to today using a required rate of return, giving an estimate of what the business could be worth in total right now. For Celcuity, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in $. The latest twelve month free cash flow is a loss of $144.9 million. Analyst estimates and subsequent extrapolations then project free cash flow moving to $766.9 million by 2030, with a series of annual figures between 2026 and 2035, some of which are still negative early in the forecast period and then turn positive later on. Discounting these projected cash flows back to today gives an estimated intrinsic value of about $550.51 per share. Compared with the current share price, this implies an intrinsic discount of 80.6%, which indicates that the shares screen as materially undervalued based on this DCF output. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Celcuity is undervalued by 80.6%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks. CELC Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Celcuity. Approach 2: Celcuity Price vs Book For asset focused or early stage companies where earnings and revenue based metrics are less informative, the P/B ratio is often a practical way to gauge what investors are paying relative to the company’s net assets. Higher growth expectations or lower perceived risk can support a higher P/B multiple, while slower growth or higher risk usually points to a lower, more conservative range. Celcuity currently trades on a P/B of 42.23x. This sits well above the Biotechs industry average P/B of 2.63x and also above the peer group average of 13.54x. This indicates that the market is assigning a much higher value to each dollar of Celcuity’s book value than to many of its sector peers. Simply Wall St’s Fair Ratio is designed to refine that comparison by estimating what a more appropriate P/B might be for Celcuity after factoring in elements like its earnings profile, growth outlook, profit margins, industry, market size and identified risks. Because it adjusts for these company specific characteristics, it can give you a more tailored reference point than a simple industry or peer comparison. In this case, the Fair Ratio for Celcuity is not available, so there is no clear signal on whether the current 42.23x P/B suggests the shares are overvalued or undervalued on this basis. Result: ABOUT RIGHT NasdaqCM:CELC P/B Ratio as at Feb 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies. Upgrade Your Decision Making: Choose your Celcuity Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative is simply your story about a company, written in numbers, where you connect your view on its products, pipeline and risks to specific assumptions for future revenue, earnings and margins, which then roll into a forecast and a fair value estimate. On Simply Wall St, Narratives sit inside the Community page and are designed to be easy to use so you can compare your own view of Celcuity with those of millions of other investors. Each Narrative links straight through to a clear decision point by setting a Fair Value that you can line up against the current share price to help you decide whether you see more upside or downside. Narratives are also refreshed as new information such as earnings results or company news becomes available, so the story and the numbers stay aligned. For Celcuity, one investor might set a very optimistic Fair Value based on strong confidence in the pipeline, while another might choose a much lower Fair Value that reflects a more cautious stance on execution and funding. Do you think there's more to the story for Celcuity? Head over to our Community to see what others are saying! NasdaqCM:CELC 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609526849","isCrawlerRequest":true}